Log In
BCIQ
Print this Print this
 

RVC58

  Manage Alerts
Collapse Summary General Information
Company Humabs BioMed S.A.
DescriptionAntibody targeting antigenic site III of rabies virus (RABV) glycoprotein
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationRabies
Indication DetailsTreat rabies infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today